Extension Study of rhuFab V2 in Subjects With Neovascular Age-Related Macular Degeneration (AMD)

Sponsor
Genentech, Inc.
Study ID
NCT00095433
Phase
PHASE3
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
50 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This is a Phase III, open-label, multicenter extension study of intravitreally administered ranibizumab in subjects with primary or recurrent subfoveal choroidal neovascularization (CNV) secondary to AMD who have completed the treatment phase of a Genentech sponsored Phase I or Phase I/II ranibizumab protocol (FVF1770g, FVF2128g, or FVF2425g).

Key Dates

First listed
Nov 5, 2004
Start date
Sep 30, 2002
Status verified
Mar 2014
Primary completion
Aug 31, 2006
Completion
Aug 31, 2006

Study Design

Enrollment
100 participants
Primary purpose
TREATMENT

Related Studies